Jiangxi Fushine Pharmaceutical Hits Day Low Amid Price Pressure at CNY 16.76

Jiangxi Fushine Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 9.95% and reaching an intraday low of CNY 16.76. This performance stands in contrast to the broader market, as the China Shanghai Composite index fell by only 3.05% on the same day. Over the past week, Jiangxi Fushine has seen a decrease of 6.66%, while its monthly performance reflects a decline of 6.15%. However, the company has shown resilience over the longer term, boasting a remarkable 66.02% increase in stock value over the past year, significantly outperforming the China Shanghai Composite's 7.03% gain. Despite the recent downturn, Jiangxi Fushine has reported positive financial metrics, including a substantial growth in net profit of 692.07% in its latest quarterly results. The company remains net-debt free and has demonstrated strong performance in terms of net sales, which grew by 20.76% in the most recent quarter. However, its long-term fundamentals indicate a weak return on capital employed (ROCE) of 4.17%, raising concerns about future growth potential.